Abortion, Induced Clinical Trial
Official title:
A Pilot Study of Priming Before Induction Termination of Pregnancy
Induction termination of pregnancy (second trimester abortion) has a median time of 14 hours
from the start of medication (misoprostol) to expulsion of the fetus. The objective of this
study is to evaluate a method of 'priming' on the length of induction termination of
pregnancy. "Priming" refers to the use of medication to ready the cervix and uterus so that
the uterus is more sensitive to medication and contracts more effectively, and also refers
to softening of the cervix so that there is less resistance to dilation. Priming is used
extensively before induction of labor for term pregnancy and is also used extensively before
surgical abortion in second trimester. We would like to add priming the evening before
induction to the usual treatment and evaluate whether the length of the induction process is
shortened. Women are admitted to the hospital in the morning to start misoprostol
medication, and unless expulsion occurs within 8-10 hours, need to stay overnight.
The study design is to give the priming dose 12 hours before admission. The outcome of
interest is the induction time from the first dose on misoprostol in the hospital to
expulsion of the fetus.
This study aims to assess whether the use of misoprostol as a priming agent would be
beneficial with women who undergo induction termination of pregnancy.
This is a prospective series. All women enrolled will receive the same treatment. 10 women
without prior births and 10 women with prior births will be enrolled. The study design is to
give the priming dose 12 hours before admission.
The outcome of interest is the induction time from the first dose on misoprostol in the
hospital to expulsion of the fetus.
Inclusion criteria: Women who have requested induction abortion and completed the counseling
and consent process for abortion. Women 18 years of age or over. Capable of giving informed
consent. Speak English or Spanish Pregnancy 18-23 weeks. No contraindication to misoprostol
abortion
Exclusion criteria: Unable to understand and give informed consent. Pregnancy less than 18
weeks or over 23 weeks on the day of enrollment. Ruptured membranes or signs of infection
(temperature over 100.6 F,WBC >15K) Fetal demise Multi-fetal pregnancy Contraindication to
any of the agents used for misoprostol induction abortion
After women have started the abortion process (completed counseling and consent for
abortion, and completed the fetocidal digoxin injection), they will be approached by one of
the investigators. The procedures and the consent process will be explained. If they
consent, they will be given an envelope which contains 50 mcg of misoprostol (1/2 of a 100
mcg tablet). They will be instructed to place the tablet buccally and hold it in place for
30 minutes, after which it can be swallowed, between 8 and 9 pm that evening.
They will return at 7 am the next morning; the actual induction process starts between 8 and
10 am depending on the bed situation. The reminder of the care is identical to women not in
the study and consists of misoprostol 400 every 6 hours. The only step that will be from the
current induction process is the administration of the priming dose the night before.
The duration of participation for individuals is up to 48 hours. The study overall will take
one year.
Analytic plan:
This is a pilot study to estimate the effect on induction times, and to monitor for any
adverse events. This pilot will be the basis of further study.
When the sample size is 19, a two-sided 95.0% confidence interval for a single mean will
have an interval that extends no more than 1.5 from the observed mean, assuming that the
true standard deviation is 3.25 and that the confidence interval is based on the t
statistic. The "typical" mean is 14 hours and the 95% confidence interval around 12.5 hours
is 11hours to 14 hours.
The primary outcome is the induction time, the time from start of induction until fetal
expulsion. As there are about 80 induction procedures per year, and past studies have
enrolled 50-60% of eligible women, it will take approximately 6 months to complete
enrollment.
The length of induction will be described and the mean will be contrasted to a typical value
(14 hours) . Minor events such as nausea will be tabulated. There will be a sub-analysis of
outcome by parity (women without prior births compared to women with prior births). This
study is not powered to show differences between these two groups but this information wil
be helpful in planning future studies.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01541293 -
Intrauterine Lidocaine for Laminaria
|
Phase 1 | |
Completed |
NCT00177333 -
Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens
|
Phase 4 | |
Completed |
NCT00370487 -
Comparison of the Safety of First Trimester Abortions Performed by Physicians and Non-Physicians in South Africa and Viet Nam.
|
N/A | |
Completed |
NCT00188071 -
Postoperative Pain After Medical Abortion Under Local Anesthesia : Comparison of Several Analgesic Regimen
|
N/A | |
Completed |
NCT02277249 -
Transvaginal Versus Transabdominal Digoxin Prior to Second-trimester Abortion
|
N/A | |
Completed |
NCT00386867 -
A Randomized Trial of Buccal Compared to Oral Misoprostol Following Mifepristone for Medical Abortion up to 63 Days LMP
|
N/A | |
Completed |
NCT00677755 -
Medical Abortion for Emergency Contraception Failure
|
N/A | |
Completed |
NCT02279914 -
Misoprostol Dose and Timing Before Surgical Abortion at 13 to 16 Weeks' Gestation: a Randomized Trial
|
N/A | |
Completed |
NCT01597726 -
Cervical Priming Before Dilation & Evacuation
|
N/A | |
Completed |
NCT01615731 -
Value of Mifepristone in Cervical Preparation Prior to Dilation and Evacuation 19-24 Weeks
|
N/A | |
Completed |
NCT02318212 -
Dilapan-S / Dilasoft E-Registry in Induced Abortion
|
N/A | |
Terminated |
NCT00855842 -
Pilot Study of the Addition of Osmotic Dilators to Preparation Prior to Labor Induction Abortion
|
N/A | |
Completed |
NCT00330993 -
Oral Mifepristone and Buccal Misoprostol Administered Simultaneously for Abortion Through 63 Days Gestation
|
Phase 2 | |
Completed |
NCT00382538 -
Mifepristone and Mid-Trimester Termination of Pregnancy
|
N/A | |
Completed |
NCT03080493 -
Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial
|
Phase 4 | |
Completed |
NCT02485444 -
Oxytocin Infusion vs. Spontaneous Follow-up for Third-stage of Labor After Second-trimester Abortion
|
Phase 4 | |
Completed |
NCT00969982 -
Mifepristone Plus Misoprostol Versus Misoprostol Alone for 2nd Trimester Abortion (14 - 21 Weeks Last Menstrual Period (LMP))
|
N/A | |
Recruiting |
NCT02480543 -
Different Routes of Misoprostol Prior to First Trimester Surgical Abortion
|
Phase 4 | |
Completed |
NCT00870272 -
Study of 400mcg Sublingual Versus 400mcg Buccal Misoprostol Following 200mg Mifepristone for Medical Abortion up to 63 Days Last Menstrual Period (LMP)
|
N/A | |
Completed |
NCT02048098 -
Misoprostol for Second Trimester Termination of Pregnancy
|
Phase 3 |